Effect of Mirabegron on Bladder Compliance

Inclusion Criteria: Patients over 19 years of age Bladder compliance is 20ml/cmH2O or less Patient who has been treated with antimuscarinic for at least 1 month, but has not been effective. Patient who agrees to and signs the informed consent Exclusion Criteria: Those who have taken clinical drugs with other ingredients (other than this experiment) for the past 60 days or participated in clinical trials using other types of medical devices. Those who have previously undergone bladder augmentation Those who currently have an indwelled catheter for urination Those with abnormal findings in renal function (serum creatinine >2 mg/dL) Those with abnormal liver function (serum AST/ALT >2 times upper limit, GGT >3 times upper limit of normal,total bilirubin >2 times upper limit of normal) Those with a history of bladder cancer before screening Those who were diagnosed with interstitial cystitis Those with active UTI Those who are pregnant or breastfeeding Those with a history of previous treatment with mirabegron Those who are allergic to beta 3 agonist, who are expected to be allergic to mirabegron Those confirmed as resting SBP >180 mmHg and/or DBP >110 mmHg Those confirmed as resting HR >100 beats per minute Male patients who are likely to become pregnant or donate sperm during the study period or within 28 days of the last drug administration of the study. Those who do not respond to surveys and research follow-up visits Those for whom the researcher judges that the treatment method of this study is not the best treatment for the patient